FDMT
4D Molecular Therapeutics Inc
14.70$
-1.9%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.8% | – | -103,885.7% | -604,860.0% | -979,700.0% | -4,586,300.0% | -341,128.6% | -289,180.0% | -51,664.4% | 33.6% | -2,235.8% | -1,851.3% | -169.6% | |
| 6.9% | – | 5,692.9% | 32,480.0% | 56,766.7% | 178,400.0% | 12,528.6% | 12,586.7% | 2,225.6% | 2.3% | 67.4% | 13.1% | 7.1% | |
| 22.6% | – | 21,335.7% | 121,460.0% | 216,333.3% | 757,800.0% | 49,900.0% | 33,053.3% | 5,021.1% | 6.5% | 146.1% | 155.6% | 22.2% | |
| 15.3% | – | -12,571.4% | -13,760.0% | 282,100.0% | -371,800.0% | -51,221.4% | 37,260.0% | 5,554.4% | 3.2% | -155.9% | -94.6% | -0.6% | |
| 2.0% | – | 2,535.7% | 6,980.0% | 59,266.7% | 94,900.0% | 4,507.1% | 440.0% | 101.1% | 0.7% | 0.0% | 1.5% | 0.8% | |
| 148.4% | – | -940,207.1% | -1,470,780.0% | 910,033.3% | 705,900.0% | 228,200.0% | -92,346.7% | 19,753.3% | -151.4% | 2,260.8% | 675.6% | -18.1% | |
| – | – | – | – | – | – | – | – | – | 8.8% | – | – | – | |
| 52.3% | – | 1,138,685.7% | 344,980.0% | 18,933.3% | 60,100.0% | 0.0% | 5,746.7% | 128.9% | 131.6% | 376.9% | 1,119.8% | 180.3% | |
| 194.8% | – | 94,592.9% | -1,730,660.0% | -50,733.3% | -3,820,300.0% | -112,928.6% | -425,366.7% | -31,782.2% | 13.7% | 401.9% | -56.0% | -7.4% | |
| -7.8% | – | -106,421.4% | -611,840.0% | -1,038,966.7% | -4,681,200.0% | -345,635.7% | -289,620.0% | -51,563.3% | 32.8% | -2,235.8% | -1,852.8% | -170.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.